SGLT-2 inhibitors for kidney disease in lupus and vasculitis
Part of Heart & circulation, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests if a type of diabetes medicine (SGLT-2 inhibitors) can reduce protein in the urine and protect kidney function in people with chronic kidney disease caused by lupus nephritis or ANCA-associated vasculitis. The medicine is already approved for other conditions, and researchers want to see if it works for these kidney diseases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have chronic kidney disease (stage 1, 2, or 3) caused by lupus nephritis or ANCA-associated vasculitis
- Your lupus nephritis is currently not active (not in a flare)
- Your kidney function (eGFR) is 30 or higher
- You do not have diabetes (type 1 or type 2)
- You have not taken an SGLT-2 inhibitor in the last month and you do not have frequent urinary tract infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a diabetes drug called dapagliflozin can help people with active lupus nephritis by reducing protein in the urine and preserving kidney function. It is given in addition to standard treatments.
This trial tests if empagliflozin, a medicine used for diabetes, can help protect kidney function in people with active lupus nephritis. You may be eligible if you have a lupus kidney flare with significant protein in your urine.
This study tests if an SGLT2 inhibitor can help protect kidney function in people who have lupus nephritis (kidney inflammation caused by lupus) and chronic kidney disease (CKD). The goal is to see if this medicine can slow down further kidney damage.
This trial tests whether SGLT2 inhibitor drugs can protect kidney function in people with advanced chronic kidney disease who are not yet on dialysis. It may help slow further kidney decline.
This study tests how a drug called canagliflozin (an SGLT2 inhibitor) affects kidney function in people with type 2 diabetes. It involves two kidney biopsies to see how the drug works inside your kidneys, aiming to better protect kidney health.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
Hear when a new Lupus Nephritis (LN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.